Kaya, Ali OsmanCoskun, UgurGumus, MahmutDane, FaysalOzkan, MetinIsikdogan, AbdurrahmanAlkis, Necati2024-04-242024-04-2420121120-009Xhttps://doi.org/10.1179/1973947812Y.0000000020https://hdl.handle.net/11468/18193There is no established standard salvage chemotherapy in the second-line setting for patients with advanced gastric cancer (AGC) pre-treated with platinum and taxane-based chemotherapy. Our study aims to evaluate the safety and efficacy of FOLFIRI regimen (irinotecan with leucovorin and bolus and continuous infusion with 5-fluorouracil) as a salvage chemotherapy regimen in patients with AGC. Medical records of 97 patients with AGC who received second-line FOLFIRI regimen between March 2006 and February 2011 were examined. Complete and partial responses were observed in 3 (3.1%) and 23 (23.7%) patients, respectively. The median time to progression (TTP) was 3.5 months (95% CI: 2.4-4.6) and the median overall survival (OS) was 10.5 months (95% CI: 8.8-12.2). The most common observed grade 3/4 toxicities were neutropenia (23.7%), diarrhea (6.2%), and stomatitis (5.2%). FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes.eninfo:eu-repo/semantics/closedAccessAdvanced Gastric CancerSalvage TherapyFolfiri RegimenArticle244217220WOS:0003070134000072-s2.0-848662490192304068610.1179/1973947812Y.0000000020Q3Q4